0QFP.LSE Gedeon Richter PLC
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0QFP.LSE undervalued?
Graham numberThe Graham number of Gedeon Richter PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gedeon Richter PLC fundamental analysis
No fundamental analysis for Gedeon Richter PLC yet.
Gedeon Richter PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gedeon Richter PLC
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-a…
Full company profileGedeon Richter PLC financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gedeon Richter PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 390B | 444B | 445B | 508B | 567B | - | - | - |
| Gross Profit | 226B | 253B | 254B | 278B | 319B | - | - | - |
| Operating Income | 54.6B | 20.7B | 45.0B | 39.9B | 112B | - | - | - |
| Net Income | 66.2B | 8.89B | 35.3B | 47.1B | 105B | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 814B | 761B | 798B | 859B | 949B | - | - | - |
| Total Liabilities | 136B | 102B | 118B | 141B | 142B | - | - | - |
| Shareholders' Equity | 678B | 659B | 680B | 718B | 807B | - | - | - |
| Cash & Short-term Investments | 96.8B | 76.1B | 118B | 130B | 149B | - | - | - |
| Total Debt | 28.9B | 3.00M | 2.00M | 10.3B | 10.8B | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 77.4B | 83.7B | 100B | 98.2B | 134B | 140B | 185B | - |
| Capital Expenditure | 36.5B | 39.9B | 42.0B | 39.5B | 36.9B | 46.1B | 59.2B | 0.00 |
| Ratios | ||||||||
| ROE | 9.8% | 1.3% | 5.2% | 6.6% | 13.0% | - | - | - |
| ROA | 8.1% | 1.2% | 4.4% | 5.5% | 11.0% | - | - | - |
| Net Profit Margin | 17.0% | 2.0% | 7.9% | 9.3% | 18.5% | - | - | - |
| Debt to Equity | 0.04x | 0.00x | 0.00x | 0.01x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gedeon Richter PLC dividends
Gedeon Richter PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 10:1 on Jul 11, 2013.
Who owns Gedeon Richter PLC
- Insiders 25.25%
- Institutions 39.40%
- Public & others 35.35%
- Free float 182M
Gedeon Richter PLC company profile
- Company name
- Gedeon Richter PLC
- Ticker
- 0QFP.LSE
- ISIN
- HU0000123096
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 11,155
- Fiscal year end
- December
- Address
- Gyömroi út 19-21, Budapest, Hungary, 1103
- Phone
- 36 1 431 4000
- Website
- gedeonrichter.com
About Gedeon Richter PLC
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Gedeon Richter PLC management
5- Mr. Gabor OrbanCEO & Director · born 1979
- Mr. Laszlo Andras KovacsGroup Head of Controlling, CFO & Director
- Ms. Katalin ErdeiHuman Resources & Technical Director · born 1974
- Mr. Robert RethyHead of the Investor Relations & ESG Department
- Mr. Tamas SzolyakDirector of Global Regulatory Science, Commerce & Marketing · born 1966